Update on the pathogenesis of bullous pemphigoid: An autoantibody-mediated blistering disease targeting collagen XVII

Journal of Dermatological Science

Volumn 73, Issue 3, 2014, Pages 179-186

  Nishie, Wataru ^a  

^a HOKKAIDO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Autoantibody; Complement activation; IgE; Model mice; Protease

Indexed keywords

AUTOANTIBODY; COMPLEMENT ACTIVATION; IGE; MODEL MICE; PROTEASE;

AMINO ACID SEQUENCE; ANIMALS; AUTOANTIBODIES; AUTOANTIGENS; COMPLEMENT SYSTEM PROTEINS; HUMANS; IMMUNOGLOBULIN E; INFLAMMATION; MOLECULAR SEQUENCE DATA; NON-FIBRILLAR COLLAGENS; PEMPHIGOID, BULLOUS;

EID: 84895094644     PISSN: 09231811     EISSN: 1873569X     Source Type: Journal    
DOI: 10.1016/j.jdermsci.2013.12.001     Document Type: Review

References (62)

1. Stanley J.R. Pemphigus and pemphigoid as paradigms of organ-specific, autoantibody-mediated diseases. J Clin Invest 1989, 83:1443-1448.
2. Schmidt E., Zillikens D. Pemphigoid diseases. Lancet 2013, 381:320-332.
3. Langan S.M., Groves R.W., West J. The relationship between neurological disease and bullous pemphigoid: a population-based case-control study. J Invest Dermatol 2011, 131:631-636.
4. Seppanen A., Autio-Harmainen H., Alafuzoff I., Sarkioja T., Veijola J., Hurskainen T., et al. Collagen XVII is expressed in human CNS neurons. Matrix Biol 2006, 25:185-188.
5. Delgado J.C., Turbay D., Yunis E.J., Yunis J.J., Morton E.D., Bhol K., et al. A common major histocompatibility complex class II allele HLA-DQB1* 0301 is present in clinical variants of pemphigoid. Proc Natl Acad Sci U S A 1996, 93:8569-8571.
6. Zakka L.R., Reche P., Ahmed A.R. Role of MHC Class II genes in the pathogenesis of pemphigoid. Autoimmun Rev 2011, 11:40-47.
7. della Torre R., Combescure C., Cortes B., Marazza G., Beltraminelli H., Naldi L., et al. Clinical presentation and diagnostic delay in bullous pemphigoid: a prospective nationwide cohort. Br J Dermatol 2012, 167:1111-1117.
8. Korman N. Bullous pemphigoid. J Am Acad Dermatol 1987, 16:907-924.
9. Sardy M., Kostaki D., Varga R., Peris K., Ruzicka T. Comparative study of direct and indirect immunofluorescence and of bullous pemphigoid 180 and 230 enzyme-linked immunosorbent assays for diagnosis of bullous pemphigoid. J Am Acad Dermatol 2013, 69:748-753.
10. McMillan J.R., Akiyama M., Shimizu H. Epidermal basement membrane zone components: ultrastructural distribution and molecular interactions. J Dermatol Sci 2003, 31:169-177.
11. Diaz L.A., Ratrie H., Saunders W.S., Futamura S., Squiquera H.L., et al. Isolation of a human epidermal cDNA corresponding to the 180-kDa autoantigen recognized by bullous pemphigoid and herpes gestationis sera. Immunolocalization of this protein to the hemidesmosome. J Clin Invest 1990, 86:1088-1094.
12. Giudice G.J., Squiquera H.L., Elias P.M., Diaz L.A. Identification of two collagen domains within the bullous pemphigoid autoantigen, BP180. J Clin Invest 1991, 87:734-738.
13. Groves R.W., Liu L., Dopping-Hepenstal P.J., Markus H.S., Lovell P.A., Ozoemena L., et al. A homozygous nonsense mutation within the dystonin gene coding for the coiled-coil domain of the epithelial isoform of BPAG1 underlies a new subtype of autosomal recessive epidermolysis bullosa simplex. J Invest Dermatol 2010, 130:1551-1557.
14. Gatalica B., Pulkkinen L., Li K., Kuokkanen K., Ryynanen M., McGrath J.A., et al. Cloning of the human type XVII collagen gene (COL17A1), and detection of novel mutations in generalized atrophic benign epidermolysis bullosa. Am J Hum Genet 1997, 60:352-365.
15. Ishiko A., Shimizu H., Kikuchi A., Ebihara T., Hashimoto T., Nishikawa T. Human autoantibodies against the 230-kDa bullous pemphigoid antigen (BPAG1) bind only to the intracellular domain of the hemidesmosome, whereas those against the 180-kDa bullous pemphigoid antigen (BPAG2) bind along the plasma membrane of the hemidesmosome in normal human and swine skin. J Clin Invest 1993, 91:1608-1615.
16. Thoma-Uszynski S., Uter W., Schwietzke S., Schuler G., Borradori L., Hertl M. Autoreactive T and B cells from bullous pemphigoid (BP) patients recognize epitopes clustered in distinct regions of BP180 and BP230. J Immunol 2006, 176:2015-2023.
17. Di Zenzo G., Thoma-Uszynski S., Calabresi V., Fontao L., Hofmann S.C., Lacour J.P., et al. Demonstration of epitope-spreading phenomena in bullous pemphigoid: results of a prospective multicenter study. J Invest Dermatol 2011, 131:2271-2280.
18. Kiss M., Husz S., Janossy T., Marczinovits I., Molnar J., Korom I., et al. Experimental bullous pemphigoid generated in mice with an antigenic epitope of the human hemidesmosomal protein BP230. J Autoimmun 2005, 24:1-10.
19. Franzke C.W., Tasanen K., Schumann H., Bruckner-Tuderman L. Collagenous transmembrane proteins: collagen XVII as a prototype. Matrix Biol 2003, 22:299-309.
20. Tasanen K., Tunggal L., Chometon G., Bruckner-Tuderman L., Aumailley M. Keratinocytes from patients lacking collagen XVII display a migratory phenotype. Am J Pathol 2004, 164:2027-2038.
21. Nishie W., Kiritsi D., Nystrom A., Hofmann S.C., Bruckner-Tuderman L. Dynamic interactions of epidermal collagen XVII with the extracellular matrix: laminin 332 as a major binding partner. Am J Pathol 2011, 179:829-837.
22. Nonaka S., Ishiko A., Masunaga T., Akiyama M., Owaribe K., Shimizu H., et al. The extracellular domain of BPAG2 has a loop structure in the carboxy terminal flexible tail in vivo. J Invest Dermatol 2000, 115:889-892.
23. Hirako Y., Usukura J., Uematsu J., Hashimoto T., Kitajima Y., Owaribe K. Cleavage of BP180, a 180-kDa bullous pemphigoid antigen, yields a 120-kDa collagenous extracellular polypeptide. J Biol Chem 1998, 273:9711-9717.
24. Franzke C.W., Tasanen K., Schacke H., Zhou Z., Tryggvason K., Mauch C., et al. Transmembrane collagen XVII, an epithelial adhesion protein, is shed from the cell surface by ADAMs. EMBO J 2002, 21:5026-5035.
25. Hirako Y., Nishizawa Y., Sitaru C., Opitz A., Marcus K., Meyer H.E., et al. The 97-kDa (LABD97) and 120-kDa (LAD-1) fragments of bullous pemphigoid antigen 180/type XVII collagen have different N-termini. J Invest Dermatol 2003, 121:1554-1556.
26. Nishie W., Lamer S., Schlosser A., Licarete E., Franzke C.W., Hofmann S.C., et al. Ectodomain shedding generates Neoepitopes on collagen XVII, the major autoantigen for bullous pemphigoid. J Immunol 2010, 185:4938-4947.
27. Zillikens D., Rose P.A., Balding S.D., Liu Z., Olague-Marchan M., Diaz L.A., et al. Tight clustering of extracellular BP180 epitopes recognized by bullous pemphigoid autoantibodies. J Invest Dermatol 1997, 109:573-579.
28. Fairley J.A., Fu C.L., Giudice G.J. Mapping the binding sites of anti-BP180 immunoglobulin E autoantibodies in bullous pemphigoid. J Invest Dermatol 2005, 125:467-472.
29. Liu Z., Diaz L.A., Troy J.L., Taylor A.F., Emery D.J., Fairley J.A., et al. A passive transfer model of the organ-specific autoimmune disease, bullous pemphigoid, using antibodies generated against the hemidesmosomal antigen, BP180. J Clin Invest 1993, 92:2480-2488.
30. Nishie W., Sawamura D., Goto M., Ito K., Shibaki A., McMillan J.R., et al. Humanization of autoantigen. Nat Med 2007, 13:378-383.
31. Liu Z., Sui W., Zhao M., Li Z., Li N., Thresher R., et al. Subepidermal blistering induced by human autoantibodies to BP180 requires innate immune players in a humanized bullous pemphigoid mouse model. J Autoimmun 2008, 31:331-338.
32. Di Zenzo G., Calabresi V., Olasz E.B., Zambruno G., Yancey K.B. Sequential intramolecular epitope spreading of humoral responses to human BPAG2 in a transgenic model. J Invest Dermatol 2010, 130:1040-1047.
33. Ujiie H., Shibaki A., Nishie W., Sawamura D., Wang G., Tateishi Y., et al. A novel active mouse model for bullous pemphigoid targeting humanized pathogenic antigen. J Immunol 2010, 184:2166-2174.
34. Kobayashi M., Amagai M., Kuroda-Kinoshita K., Hashimoto T., Shirakata Y., Hashimoto K., et al. BP180 ELISA using bacterial recombinant NC16a protein as a diagnostic and monitoring tool for bullous pemphigoid. J Dermatol Sci 2002, 30:224-232.
35. Di Zenzo G., Thoma-Uszynski S., Fontao L., Calabresi V., Hofmann S.C., Hellmark T., et al. Multicenter prospective study of the humoral autoimmune response in bullous pemphigoid. Clin Immunol 2008, 128:415-426.
36. Zillikens D., Herzele K., Georgi M., Schmidt E., Chimanovitch I., Schumann H., et al. Autoantibodies in a subgroup of patients with linear IgA disease react with the NC16A domain of BP1801. J Invest Dermatol 1999, 113:947-953.
37. Nie Z., Nagata Y., Joubeh S., Hirako Y., Owaribe K., Kitajima Y., et al. IgA antibodies of linear IgA bullous dermatosis recognize the 15th collagenous domain of BP180. J Invest Dermatol 2000, 115:1164-1166.
38. Perriard J., Jaunin F., Favre B., Budinger L., Hertl M., Saurat J.H., et al. IgG autoantibodies from bullous pemphigoid (BP) patients bind antigenic sites on both the extracellular and the intracellular domains of the BP antigen 180. J Invest Dermatol 1999, 112:141-147.
39. Giudice G.J., Emery D.J., Zelickson B.D., Anhalt G.J., Liu Z., Diaz L.A. Bullous pemphigoid and herpes gestationis autoantibodies recognize a common non-collagenous site on the BP180 ectodomain. J Immunol 1993, 151:5742-5750.
40. Liu Z., Giudice G.J., Swartz S.J., Fairley J.A., Till G.O., Troy J.L., et al. The role of complement in experimental bullous pemphigoid. J Clin Invest 1995, 95:1539-1544.
41. Liu Z., Giudice G.J., Zhou X., Swartz S.J., Troy J.L., Fairley J.A., et al. A major role for neutrophils in experimental bullous pemphigoid. J Clin Invest 1997, 100:1256-1263.
42. Chen R., Ning G., Zhao M.L., Fleming M.G., Diaz L.A., Werb Z., et al. Mast cells play a key role in neutrophil recruitment in experimental bullous pemphigoid. J Clin Invest 2001, 108:1151-1158.
43. Nelson K.C., Zhao M., Schroeder P.R., Li N., Wetsel R.A., Diaz L.A., et al. Role of different pathways of the complement cascade in experimental bullous pemphigoid. J Clin Invest 2006, 116:2892-2900.
44. Wang G., Ujiie H., Shibaki A., Nishie W., Tateishi Y., Kikuchi K., et al. Blockade of autoantibody-initiated tissue damage by using recombinant fab antibody fragments against pathogenic autoantigen. Am J Pathol 2010, 176:914-925.
45. Li Q., Ujiie H., Shibaki A., Wang G., Moriuchi R., Qiao H.J., et al. Human IgG1 monoclonal antibody against human collagen 17 noncollagenous 16A domain induces blisters via complement activation in experimental bullous pemphigoid model. J Immunol 2010, 185:7746-7755.
46. Mihai S., Chiriac M.T., Herrero-Gonzalez J.E., Goodall M., Jefferis R., Savage C.O., et al. IgG4 autoantibodies induce dermal-epidermal separation. J Cell Mol Med 2007, 11:1117-1128.
47. Shiraishi S., Iio T., Shirakata Y., Sayama K., Nishimukai H., Miki Y. Bullous pemphigoid in a patient with a C4 deficiency. Br J Dermatol 1991, 124:296-298.
48. Schmidt E., Reimer S., Kruse N., Jainta S., Brocker E.B., Marinkovich M.P., et al. Autoantibodies to BP180 associated with bullous pemphigoid release interleukin-6 and interleukin-8 from cultured human keratinocytes. J Invest Dermatol 2000, 115:842-848.
49. Iwata H., Kamio N., Aoyama Y., Yamamoto Y., Hirako Y., Owaribe K., et al. IgG from patients with bullous pemphigoid depletes cultured keratinocytes of the 180-kDa bullous pemphigoid antigen (type XVII collagen) and weakens cell attachment. J Invest Dermatol 2009, 129:919-926.
50. Natsuga K., Nishie W., Shinkuma S., Ujiie H., Nishimura M., Sawamura D., et al. Antibodies to pathogenic epitopes on type XVII collagen cause skin fragility in a complement-dependent and -independent manner. J Immunol 2012, 188:5792-5799.
51. Hiroyasu S., Ozawa T., Kobayashi H., Ishii M., Aoyama Y., Kitajima Y., et al. Bullous pemphigoid IgG induces BP180 internalization via a macropinocytic pathway. Am J Pathol 2013, 182:828-840.
52. Yayli S., Pelivani N., Beltraminelli H., Wirthmuller U., Beleznay Z., Horn M., et al. Detection of linear IgE deposits in bullous pemphigoid and mucous membrane pemphigoid: a useful clue for diagnosis. Br J Dermatol 2011, 165:1133-1137.
53. Fairley J.A., Burnett C.T., Fu C.L., Larson D.L., Fleming M.G., Giudice G.J. A pathogenic role for IgE in autoimmunity: bullous pemphigoid IgE reproduces the early phase of lesion development in human skin grafted to nu/nu mice. J Invest Dermatol 2007, 127:2605-2611.
54. Messingham K.N., Srikantha R., DeGueme A.M., Fairley J.A. FcR-independent effects of IgE and IgG autoantibodies in bullous pemphigoid. J Immunol 2011, 187:553-560.
55. Liu Z., Shapiro S.D., Zhou X., Twining S.S., Senior R.M., Giudice G.J., et al. A critical role for neutrophil elastase in experimental bullous pemphigoid. J Clin Invest 2000, 105:113-123.
56. Liu Z., Shipley J.M., Vu T.H., Zhou X., Diaz L.A., Werb Z., et al. Gelatinase B-deficient mice are resistant to experimental bullous pemphigoid. J Exp Med 1998, 188:475-482.
57. Liu Z., Li N., Diaz L.A., Shipley M., Senior R.M., Werb Z. Synergy between a plasminogen cascade and MMP-9 in autoimmune disease. J Clin Invest 2005, 115:879-887.
58. Liu Z., Zhou X., Shapiro S.D., Shipley J.M., Twining S.S., Diaz L.A., et al. The serpin alpha1-proteinase inhibitor is a critical substrate for gelatinase B/MMP-9 in vivo. Cell 2000, 102:647-655.
59. Lin L., Betsuyaku T., Heimbach L., Li N., Rubenstein D., Shapiro S.D., et al. Neutrophil elastase cleaves the murine hemidesmosomal protein BP180/type XVII collagen and generates degradation products that modulate experimental bullous pemphigoid. Matrix Biol 2012, 31:38-44.
60. Stahle-Backdahl M., Inoue M., Guidice G.J., Parks W.C. 92-kDa gelatinase is produced by eosinophils at the site of blister formation in bullous pemphigoid and cleaves the extracellular domain of recombinant 180-kDa bullous pemphigoid autoantigen. J Clin Invest 1994, 93:2022-2030.
61. Hofmann S.C., Voith U., Schonau V., Sorokin L., Bruckner-Tuderman L., Franzke C.W. Plasmin plays a role in the in vitro generation of the linear IgA dermatosis antigen LADB97. J Invest Dermatol 2009, 129:1730-1739.
62. Verraes S., Hornebeck W., Polette M., Borradori L., Bernard P. Respective contribution of neutrophil elastase and matrix metalloproteinase 9 in the degradation of BP180 (type XVII collagen) in human bullous pemphigoid. J Invest Dermatol 2001, 117:1091-1096.